Nordion (NYSE: NDZ) announced its earnings results on Tuesday. The company reported $0.07 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.03 by $0.04. The company had revenue of $53.70 million for the quarter, compared to the consensus estimate of $53.01 million.
A number of analysts have recently weighed in on NDZ shares. Analysts at CIBC reiterated a “sector perform” rating on shares of Nordion in a research note to investors on Monday. They now have a $8.00 price target on the stock. On the ratings front, analysts at TheStreet downgraded shares of Nordion from a “hold” rating to a “sell” rating in a research note to investors on Friday, February 1st.
Two equities research analysts have rated the stock with a buy rating, three have given a hold rating, and one has assigned a sell rating to the stock. The stock currently has a consensus rating of “hold” and an average price target of $8.52.
Nordion (NDZ) traded up 1.66% on Tuesday, hitting $6.72. Nordion (NDZ) has a 1-year low of $5.51 and a 1-year high of $10.96. The stock’s 50-day moving average is currently $6.91. The company’s market cap is $416.0 million.
Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global specialty health science company that provides market-leading products and services used for the prevention, diagnosis and treatment of disease.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
